Compare Summit Therapeutics Inc (SMMT) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Value Index Fund ETF — how do they compare? Summit Therapeutics Inc trades at $17.6 (market cap $13.71B), while Vanguard Value Index Fund ETF trades at $220.6 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is far larger — about 19.1× Summit Therapeutics Inc's market cap, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| SMMT | VTV | |
|---|---|---|
Market Cap | $13.71B | $262.40B |
Volume | 6,173,057 | 3,293,281 |
Sector | Health | — |
52-Week High | $26.38 | $227.51 |
52-Week Low | $12.43 | $182.86 |
Typical Hold Time | 16 Days | 142 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
VTV trades at $220.59, up 1.09% today, with a bearish technical signal overall despite bullish moving averages. The ETF offers a 2.3% dividend yield and has attracted institutional buying, as seen with QRG Capital Management increasing its stake by 14.7% in Q3 2026. Recent news highlights value stocks outperforming growth in 2026, with VTV leading among Vanguard's large-cap offerings.
The outlook for VTV is supported by the rotation into value stocks and its low 0.03% fee, but risks include underperformance versus the S&P 500 over the long term and sensitivity to interest rate changes. Investor sentiment is mixed, balancing value's resurgence against broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
